The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Signs of an inflammatory process, in particular increased pro-inflammatory cytokines and increased levels of prostaglandine E(2) (PGE(2)), have repeatedly been described in major depression (MD). As cyclooxygenase-2 (COX-2) inhibitors inhibit the PGE(2) production and the production of pro-inflammatory cytokines, we performed a therapeutic trial with the COX-2 inhibitor celecoxib. In a prospective, double-blind, add-on study, 40 patients suffering from an acute depressive episode were randomly assigned to either reboxetine and celecoxib or to reboxetine plus placebo. After a wash-out period, 20 patients received 4-10 mg reboxetine plus placebo and 20 received reboxetine plus 400 mg celecoxib for 6 weeks. The treatment effect was calculated by analysis of variance. There were no significant differences between groups in age, sex, duration or severity of disease or psychopathology, or reboxetine dose or plasma levels. Over 6 weeks, both groups of patients showed significant improvement in scores of the Hamilton Depression Scale. However, the celecoxib group showed significantly greater improvement compared to the reboxetine-alone group. Additional treatment with celecoxib has significant positive effects on the therapeutic action of reboxetine with regard to depressive symptomatology. Moreover, the fact that treatment with an anti-inflammatory drug showed beneficial effects on MD indicates that inflammation is related to the pathomechanism of the disorder, although the exact mechanisms remain to become elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients in the reboxetine plus celecoxib group exhibited reductions in depression severity that were nearly twice as great (55% reduction) as those experienced by patients in the control group (33% reduction).”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“TNFα antagonists such as etanercept or infliximab and the COX-2 inhibitor celecoxib have all been found to alleviate depressive symptoms in double-blind, randomized, placebo-controlled studies”
From From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. (2014) · cites this paper as Müller et al., 2006
In the citing paper
“One study found positive effects on mood in medically healthy, major depressed patients.52”
From Association of depressive disorders, depression characteristics and antidepressant medication with inflammation (2012) · cites this paper as [52]
In the citing paper
“from the administration of COX2 inhibitors to patients with major depression81”
From From inflammation to sickness and depression: when the immune system subjugates the brain (2008) · cites this paper as [81]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The global burden of disease, 1990–2020
Lopez, A. D., & Murray, C. C. J. L. (1998) · Nature Medicine · doi:10.1038/3218 · Cited by 1,614
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
Müller, N., Riedel, M., Scheppach, C., Brandstätter, B., Sokullu, S., Krampe, K., Ulmschneider, M., Engel, R. R., Möller, H.-J., & Schwarz, M. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1029 · Cited by 388
Self-citationFrommberger, U. H., Bauer, J., Haselbauer, P., Fräulin, A., Riemann, D., & Berger, M. (1997) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02900219 · Cited by 362
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 236
Song, C., Lin, A., Bonaccorso, S., Heide, C., Verkerk, R., Kenis, G., Bosmans, E., Scharpe, S., Whelan, A., Cosyns, P., et al. (1998) · Journal of Affective Disorders · doi:10.1016/s0165-0327(98)00025-1 · Cited by 232
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848
“Similarly, medically healthy depressed patients who received the selective cyclooxygenase-2 inhibitor, celecoxib, in combination with reboxetine showed greater symptomatic improvement versus patients randomized to reboxetine plus placebo (19).”
Slavich, G. M., & Irwin, M. R. (2014) · Psychological Bulletin · doi:10.1037/a0035302 · Cited by 2,206
“Moreover, 75% of patients receiving reboxetine plus celecoxib were categorized as responders, compared to only 45% of patients receiving reboxetine plus placebo (Müller et al., 2006; see also Akhondzadeh et al., 2009).”
MethodResultBelmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480
Immune system to brain signaling: Neuropsychopharmacological implications
Capuron, L., & Miller, A. H. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.014 · Cited by 1,195
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders
Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00044 · Cited by 1,189
“In line with that, treatment with anti-inflammatory agents has the potential to reduce depressive symptoms (110).”
BackgroundInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
“Nevertheless, both studies involved small sample sizes, and in the celecoxib study, 50% or more of the sample in each group dropped out before conclusion of the study (Muller et al, 2006).”
ResultKöhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
The vascular depression hypothesis: mechanisms linking vascular disease with depression
Taylor, W. D., Aizenstein, H. J., & Alexopoulos, G. S. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.20 · Cited by 923
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
Khandaker, G. M., Pearson, R. M., Zammit, S., Lewis, G., & Jones, P. B. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1332 · Cited by 846
Osimo, E. F., Baxter, L. J., Lewis, G., Jones, P. B., & Khandaker, G. M. (2019) · Psychological Medicine · doi:10.1017/s0033291719001454 · Cited by 774
“Anti-inflammatory treatment has antidepressant effects (Müller et al., 2006; Köhler et al., 2014; Kappelmann et al., 2018).”
BackgroundNeuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
“2006 [238] RCT Celecoxib (200 mg bid) + reboxetine versus placebo + reboxetine 40 MDD (acute) Significantly greater decrease in depressive symptoms in the treatment group (P = 0.”
Inflammation-associated depression: From serotonin to kynurenine
Dantzer, R., O’Connor, J. C., Lawson, M. A., & Kelley, K. W. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.09.012 · Cited by 726
Lamers, F., Vogelzangs, N., Merikangas, K. R., de Jonge, P., Beekman, A. T. F., & Penninx, B. W. J. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.144 · Cited by 691
Bercik, P., Verdu, E. F., Foster, J. A., Macri, J., Potter, M., Huang, X., Malinowski, P., Jackson, W., Blennerhassett, P., Neufeld, K. A., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.063 · Cited by 674
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Self-citationIntegrating neuroimmune systems in the neurobiology of depression
Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.69 · Cited by 668
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Kappelmann, N., Lewis, G., Dantzer, R., Jones, P. B., & Khandaker, G. M. (2018) · Molecular Psychiatry · doi:10.1038/mp.2016.167 · Cited by 659
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Pace, T. W. W., Hu, F., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.08.009 · Cited by 621
Inflamed moods: A review of the interactions between inflammation and mood disorders
Rosenblat, J. D., Cha, D. S., Mansur, R. B., & McIntyre, R. S. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.01.013 · Cited by 609
Cytokine Alterations in Bipolar Disorder: A Meta-Analysis of 30 Studies
Modabbernia, A., Taslimi, S., Brietzke, E., & Ashrafi, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.007 · Cited by 596
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
“There is also increasing evidence that anti-inflammatory drugs may have antidepressant effects in MDD patients (Muller et al., 2006, Tyring et al., 2006, Raison et al., 2013, Kohler et al., 2014).”
BackgroundThe inflammasome: Pathways linking psychological stress, depression, and systemic illnesses
Iwata, M., Ota, K. T., & Duman, R. S. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.12.008 · Cited by 580
“008 significantly augments antidepressant efficacy (Muller et al., 2006).”
InfluentialThe link between multiple sclerosis and depression
Feinstein, A., Magalhaes, S., Richard, J.-F., Audet, B., & Moore, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.139 · Cited by 523
Moylan, S., Maes, M., Wray, N. R., & Berk, M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.33 · Cited by 529
Is depression an inflammatory disorder?
Raison, C. L., & Miller, A. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0232-0 · Cited by 524
Lindqvist, D., Janelidze, S., Hagell, P., Erhardt, S., Samuelsson, M., Minthon, L., Hansson, O., Björkqvist, M., Träskman-Bendz, L., & Brundin, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.030 · Cited by 524
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“Clinical trials have shown adjunctive antidepressant effects of celecoxib [3, 5, 6, 38] and statin [57, 58] treatment among acute depressed patients already after 4-6 weeks without increased risk for cardiovascular or gastrointestinal adverse events [7].”
BackgroundResultInfluentialHow might circadian rhythms control mood? Let me count the ways
McClung, C. A. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.02.019 · Cited by 507
Functional Biomarkers of Depression: Diagnosis, Treatment, and Pathophysiology
Schmidt, H. D., Shelton, R. C., & Duman, R. S. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.151 · Cited by 474
The role of inflammation and the gut microbiome in depression and anxiety
Peirce, J. M., & Alviña, K. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24476 · Cited by 466
Anxiety disorders and inflammation in a large adult cohort
Vogelzangs, N., Beekman, A. T. F., de Jonge, P., & Penninx, B. W. J. H. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.27 · Cited by 458
Alcocer-Gómez, E., de Miguel, M., Casas-Barquero, N., Núñez-Vasco, J., Sánchez-Alcazar, J. A., Fernández-Rodríguez, A., & Cordero, M. D. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.10.017 · Cited by 443
The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia
Na, K.-S., Jung, H.-Y., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.022 · Cited by 427
Köhler‐Forsberg, O., N. Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., & Benros, M. E. (2019) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13016 · Cited by 432
Depression and frailty in later life: a systematic review
Vaughan, L., Goveas, J., & Corbin, A. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s69632 · Cited by 404
Inflammation and depression: a causal or coincidental link to the pathophysiology?
Leonard, B. E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2016.69 · Cited by 409
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Depression: an inflammatory illness?: Figure 1
Krishnadas, R., & Cavanagh, J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301779 · Cited by 392
Etiology of Depression: Genetic and Environmental Factors
Saveanu, R. V., & Nemeroff, C. B. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.12.001 · Cited by 356
A prospective evaluation of the directionality of the depression–inflammation relationship
Stewart, J. C., Rand, K. L., Muldoon, M. F., & Kamarck, T. W. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.04.011 · Cited by 390
“Furthermore, recent results suggest that medications with anti-inflammatory properties, such as cyclooxygenase-2 inhibitors (Muller et al., 2006) and tumor-necrosis factor antagonists (Tyring et al., 2006), may reduce depressive symptom severity.”
BackgroundSlavich, G. M., & Sacher, J. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05326-9 · Cited by 383
“Finally, several double-blind, randomized, placebo-controlled trials have suggested that three anti-inflammatory agents—namely, the COX-2 inhibitor, celecoxib, and the TNF-α antagonists, etanercept and infliximab—can alleviate depressive symptoms in at least some individuals (Müller et al. 2006; Raison et al. 2013; Ty…”
BackgroundAbbasi, S.-H., Hosseini, F., Modabbernia, A., Ashrafi, M., & Akhondzadeh, S. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.03.033 · Cited by 339
Khairova, R. A., Machado-Vieira, R., Du, J., & Manji, H. K. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709009924 · Cited by 350
Immune targets for therapeutic development in depression: towards precision medicine
Drevets, W. C., Wittenberg, G. M., Bullmore, E. T., & Manji, H. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00368-1 · Cited by 348
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
“Clinical trials using cyclo-oxygenase-2 inhibitors as add-on therapy in patients with treatmentresistant depression are promising (Akhondzadeh et al, 2009; Muller et al, 2006).”
MethodDepression and immunity: A role for T cells?
Miller, A. H. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.09.009 · Cited by 337
ANISMAN, H., MERALI, Z., & HAYLEY, S. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.004 · Cited by 337
The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health.
Appleton, J. (2018) · Europe PMC (PubMed Central) · Cited by 635
Cytokines and Glucocorticoid Receptor Signaling
Pace, T. W. W., & Miller, A. H. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04984.x · Cited by 339
Immune suppression and immune activation in depression
Blume, J., Douglas, S. D., & Evans, D. L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.008 · Cited by 338
Padmos, R. C., Hillegers, M. H. J., Knijff, E. M., Vonk, R., Bouvy, A., Staal, F. J. T., de Ridder, D., Kupka, R. W., Nolen, W. A., & Drexhage, H. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.395 · Cited by 336
Zunszain, P. A., Hepgul, N., & Pariante, C. M. (2012) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2012_211 · Cited by 303
Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
(2008) · PubMed · Cited by 325
Vogelzangs, N., Duivis, H. E., Beekman, A. T. F., Kluft, C., Neuteboom, J., Hoogendijk, W., Smit, J. H., de Jonge, P., & Penninx, B. W. J. H. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.8 · Cited by 323
“One study found positive effects on mood in medically healthy, major depressed patients.(52) On the other hand we found, like others,(14) that SSRI might have a beneficial effect on inflammation, suggesting that SSRI could be effective in depressed patients with immune dysregulation through this anti-inflammatory effe…”
ResultCzarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310
“…that some antidepressants, particularly serotonin reuptake inhibitors (SSRIs), act like anti-inflammatory agents, while anti-inflammatory drugs have properties of antidepressants [Xia et al. 1996, Maes et al. 1999, Müller et al. 2006, Nery et al. 2008, Hannestad et al. 2011, Abbasi et al. 2012].”
BackgroundThe Concept of Depression as a Dysfunction of the Immune System
E. Leonard, B. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823835 · Cited by 276
Spalletta, G., Bossù, P., Ciaramella, A., Bria, P., Caltagirone, C., & Robinson, R. G. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001879 · Cited by 290
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Cytokines mediated inflammation and decreased neurogenesis in animal models of depression
Song, C., & Wang, H. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.020 · Cited by 291
Anisman, H. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0902 · Cited by 292
Warner-Schmidt, J. L., Vanover, K. E., Chen, E. Y., Marshall, J. J., & Greengard, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104836108 · Cited by 291
Inflammation, Glutamate, and Glia in Depression:A Literature Review
McNally, L., Bhagwagar, Z., & Hannestad, J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016734 · Cited by 289
Neuroinflammation in Bipolar Depression
Benedetti, F., Aggio, V., Pratesi, M. L., Greco, G., & Furlan, R. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00071 · Cited by 274
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
“Interestingly, 45% of the patients in the celecoxib group showed complete remission after 6 weeks, compared with 20% in the placebo group (Müller et al., 2006).”
ResultThe role of the innate immune system in psychiatric disorders
Jones, K. A., & Thomsen, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.002 · Cited by 274
Hiles, S. A., Baker, A. L., de Malmanche, T., & Attia, J. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.06.001 · Cited by 274
Stuart, M. J., & Baune, B. T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.001 · Cited by 259
Shelton, R. C., & Miller, A. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.004 · Cited by 261
Depression and type 2 diabetes: Inflammatory mechanisms of a psychoneuroendocrine co-morbidity
Stuart, M. J., & Baune, B. T. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.10.001 · Cited by 257
Dysregulated relationship of inflammation and oxidative stress in major depression
Rawdin, B. J., Mellon, S. H., Dhabhar, F. S., Epel, E. S., Puterman, E., Su, Y., Burke, H. M., Reus, V. I., Rosser, R., Hamilton, S. P., et al. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.11.011 · Cited by 255
“Other small-scale studies also suggest antidepressant effects of anti-inflammatory medications (Muller et al., 2006; Nery et al., 2008) as well as anti-inflammatory effects of antidepressants (Abbasi et al., 2012; Felger et al., 2012; Hannestad et al., 2011).”
BackgroundLiu, R. T., Rowan-Nash, A. D., Sheehan, A. E., Walsh, R. F. L., Sanzari, C. M., Korry, B. J., & Belenky, P. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.03.026 · Cited by 242
Müller, N., Krause, D., Dehning, S., Musil, R., Schennach-Wolff, R., Obermeier, M., Möller, H.-J., Klauss, V., Schwarz, M. J., & Riedel, M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.04.015 · Cited by 250
Self-citationCold water immersion: kill or cure?
Tipton, M. J., Collier, N., Massey, H., Corbett, J., & Harper, M. (2017) · Experimental Physiology · doi:10.1113/ep086283 · Cited by 205
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Inflammation in Children and Adolescents With Neuropsychiatric Disorders: A Systematic Review
Mitchell, R. H. B., & Goldstein, B. I. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.11.013 · Cited by 244
Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders
Gibney, S. M., & Drexhage, H. A. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9462-8 · Cited by 234
The inflammation hypothesis in geriatric depression
Alexopoulos, G. S., & Morimoto, S. S. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2672 · Cited by 226
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236
Bai, S., Guo, W., Feng, Y., Deng, H., Li, G., Nie, H., Guo, G., Yu, H., Ma, Y., Wang, J., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320912 · Cited by 235
Bechter, K., Reiber, H., Herzog, S., Fuchs, D., Tumani, H., & Maxeiner, H. G. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2009.08.008 · Cited by 230
Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease
Halaris, A. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_28 · Cited by 233
Effects of Lithium on Inflammation
Nassar, A., & Azab, A. N. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500038f · Cited by 219
Systems pharmacology in drug discovery and therapeutic insight for herbal medicines
Huang, C., Zheng, C., Li, Y., Wang, Y., Lu, A., & Yang, L. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbt035 · Cited by 228
The role of cytokines in the pathophysiology of suicidal behavior
Ganança, L., Oquendo, M. A., Tyrka, A. R., Cisneros-Trujillo, S., Mann, J. J., & Sublette, M. E. (2016) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.10.008 · Cited by 217
Neuropsychiatric Disease and Toxoplasma gondii Infection
Henriquez, S. A., Brett, R., Alexander, J., Pratt, J., & Roberts, C. W. (2009) · Neuroimmunomodulation · doi:10.1159/000180267 · Cited by 206
Role of microglial m1/m2 polarization in relapse and remission of psychiatric disorders and diseases
Nakagawa, Y., & Chiba, K. (2014) · Pharmaceuticals · doi:10.3390/ph7121028 · Cited by 215
Farrell, K., & Antoni, M. H. (2010) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.03.081 · Cited by 209
Hu, V. W., Frank, B. C., Heine, S., Lee, N. H., & Quackenbush, J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-118 · Cited by 200
Metadata
- Authors
- Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., Möller, H.-J., Arolt, V, & Riedel, M.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- University of Münster (DE)
- Corresponding author
- Müller, N
- Venue
- Molecular Psychiatry
- Published
- 2006-02-21
- Volume
- 11
- Issue
- 7
- Pages
- 680-684
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2049808835
- Cited by
- 794
- References
- 37
- Citations by year
- 2026: 10 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 42 · 2021: 42 · 2020: 37 · 2019: 44 · 2018: 52 · 2017: 45 · 2016: 42 · 2015: 54 · 2014: 53 · 2013: 61 · 2012: 50
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- celecoxib, COX-2 inhibitors, major depressive disorder, reboxetine, anti-inflammatory therapy, inflammatory cytokines, prostaglandin E2, adjunctive therapy, acute depressive episode
- MeSH terms
- Celecoxib, Reboxetine, Adult, Antidepressive Agents, Depressive Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Inflammation, Lorazepam, Male, Middle Aged, Morpholines, Patient Dropouts, Pilot Projects, Psychological Tests, Pyrazoles, Serotonin, Severity of Illness Index, Sulfonamides, Anti-Anxiety Agents, Dinoprostone, Interleukin-6, Adrenergic Uptake Inhibitors, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.